Ore g o n DRE Pro g ra m Se rg e a nt E va n Se the r Ore g o n - - PowerPoint PPT Presentation

Ore g o n DRE Pro g ra m

Se rg e a nt E va n Se the r Ore g o n Sta te Po lic e

T

• pic s fo r Disc ussio n

 Ore g o n Drug Re c o g nitio n E

xpe rt (DRE ) Pro g ra m

 Wha t a re we do ing a b o ut DUI

I

• Drug s?

 Q & A

Ab o ut me

 12 Ye a rs a s a po lic e o ffic e r  8 ye a rs a s a DRE  5 ye a rs a s a DRE

I nstruc to r

 3 ye a rs a s a n E

MT

Ore g o n DRE Pro g ra m

Ove rvie w & Pro g ra m Sta ts

Ore g o n DRE Pro g ra m

 I

nte rna tio na l pro g ra m initia te d in 1987, o ve rse e n b y NHT SA a nd I ACP.

 Ore g o n’ s pro g ra m initia te d in 1995.  Curre ntly 220 DRE

s in 74 diffe re nt a g e nc ie s a c ro ss the sta te , pre do mina ntly in Va lle y a nd Me tro a re a .

 T

his re pre se nts a ppro xima te ly 4% o f a ll la w e nfo rc e me nt o ffic e rs in the Sta te o f Ore g o n.

Ore g o n DRE Pro g ra m

 Pro g ra m ma na g e d b y the Ore g o n Sta te

Po lic e – Pa tro l Se rvic e s Divisio n

 F

unde d b y ODOT g ra nts (no t inc luding sa la ry)

 T

ra ining : $230,000

 Ove rtime : $125,000  Blo o d T

e sting : $60,000

Wha t is a Drug Re c o g nitio n E xpe rt?

 Ce rtifie d la w e nfo rc e me nt o ffic e r.

 E

xpe rie nc e in DUI I / Drug e nfo rc e me nt a nd re c o mme nda tio ns fro m DRE s a nd pro se c uto rs.

 72 ho urs o f c la ssro o m tra ining .

 T

a ug ht b y DRE I nstruc to rs, physic ia ns a nd E MT s.

 40 ho urs o f fie ld c e rtific a tio n tra ining .

 Supe rvise d e va lua tio ns a nd writte n re po rts.

 Co mpre he nsive fina l kno wle dg e e xa mina tio n.  Co ntinuing e duc a tio n re q uire d.  Re -c e rtific a tio n pro c e ss e ve ry two ye a rs.

Wha t is the DRE Pro to c o l?

 12 Ste p Syste ma tic & Sta nda rdize d E

va lua tio n

 E

va lua te s sub je c t’ s me dic a l, me nta l a nd physic a l c o nditio n.

 Opinio n o f the E

va lua to r (De c isio n Pro c e ss)

 I

s the sub je c t impa ire d?

 I

f so , is it a me dic a l impa irme nt o r drug impa irme nt?

 I

f a drug impa irme nt, wha t c a te g o ry/ c a te g o rie s o f drug s a re c a using the impa irme nt?

T

• o ls the DRE

use s

 BP Cuff  Ste tho sc o pe  Ora l the rmo me te r  Pupilo me te r  I

nc a nde sc e nt Pe nlig ht

 UV lig ht  Glo ve s

De fining the te rm, “drug ”…

Any substanc e that, whe n take n into the human

body, c an impair the ability of the pe r son to

• pe r

ate a ve hic le safe ly.

Drug E va lua tio n & Cla ssific a tio n Pro g ra m

De fining the te rm, “drug ”…

Any substanc e that alte r

s pe r c e ption or be havior , r e duc ing that individual’s ability to func tion in an ac ade mic e nvir

• nme nt.

Drug I mpa irme nt T ra ining fo r E duc a tio na l Pro fe ssio na ls

I ng e stio n / Ab so rptio n E xc re tio n Distrib utio n Me ta b o lism

Why a re the re se ve n c a te g o rie s?

 E

a c h c a te g o ry c o nsists o f drug s tha t c a n impa ir a pe rso n’ s me nta l a nd physic a l a b ility.

 T

he c a te g o rie s diffe r in the wa y the drug s a ffe c t the b o dy.

 T

he c a te g o rie s diffe r in o b se rva b le sig ns a nd sympto ms o f impa irme nt.

Dura tio n o f Drug E ffe c ts

Dura tio n va rie s de pe nding o n:

 Me tho d o f I

ng e stio n

 Do sa g e  Ag e  We ig ht  T

• le ra nc e

 I

nte ra c tio ns with o the r drug s

 Psyc ho a c tive me ta b o lite s vs. ina c tive me ta b o lite s

Se ve n Drug Ca te g o rie s

Ce ntra l Ne rvo us Syste m (CNS) De pre ssa nts Ce ntra l Ne rvo us Syste m (CNS) Stimula nts Ha lluc ino g e ns

Dissoc iative Ane sthe tic s

Na rc o tic Ana lg e sic s I nha la nts Ca nna b is

Ore g o n DRE Pro g ra m Sta tistic s

 1509 drug e va lua tio ns

in 2015

 760 – Ca nna b is  436 – CNS

De pre ssa nts

 476 – CNS Stimula nts  368 – Na rc o tic

Ana lg e sic s

 7 – Ha lluc ino g e ns  7 – Disso c ia te

Ane sthe tic s

 5 – I

nha la nts

 813 (54%) we re

“po lydrug ”

 _ No t I

mpa ire d

 _ Me dic a l  _ Alc o ho l o nly

Ho w ma ny Drug DUI I s a re the re in Ore g o n?

 Are DRE

e va lua tio ns a n a c c ura te me tric fo r sta te wide DUI I

• Drug a rre sts?

 2015: 3,510 sub je c ts b le w .00% - .07% o n a n

I nto xilyze r 8000 b re a th te st instrume nt.

 Ho w did we miss 57% o f the se po te ntia l

c a ndida te s?

Ho w did we miss 2001 pe o ple ? !

 An unkno wn numb e r o f the se we re

impa ire d b y o nly a lc o ho l a nd the inve stig a tio n sto ppe d the re .

 So me sub je c ts re fuse d to pa rtic ipa te in a

DRE e va lua tio n.

 So me o ffic e rs did no t re c o g nize the sig ns o f

drug impa irme nt.

 No DRE

s we re a va ila b le to pe rfo rm the e va lua tio n.

Ho w ma ny Drug DUI I s a re the re in Ore g o n?

 T

he re is no wa y to a c c ura te ly tra c k drug DUI I s in Ore g o n.

 Da ta : who c o lle c ts it, ho w is it c o de d, e tc .  I

mplie d Co nse nt L a w do e s no t a ddre ss c o lle c tio n o f b lo o d/ urine if the sub je c t b lo ws

• ve r .08%.

 DUI

I s a re g e ne ra lly no t tra c ke d b y sub sta nc e .

Wha t do e s the DRE Pro g ra m do ?

 T

ra ining

 DRE

Sc ho o l

 Adva nc e d Ro a dside I

mpa ire d Driving E nfo rc e me nt (ARI DE )

 Drug I

mpa irme nt T ra ining fo r E duc a tio na l Pro fe ssio na ls (DI T E P)

 Pre se nta tio ns to L

e g isla ture , g o ve rnme nt g ro ups, pub lic g ro ups, stude nts, la w e nfo rc e me nt, pro se c uto rs, e tc .

Wha t do e s the DRE Pro g ra m do ?

 E

nfo rc e me nt

 DRE

E va lua tio ns

 DUI

I e nfo rc e me nt

 F

uture : T ruc ke r Che c ks

 F

uture : Hig h Visib ility E nfo rc e me nt

Wha t do e s the DRE Pro g ra m do ?

 Da ta Co lle c tio n

 DRE

e va lua tio ns

 Pre va le nc e o f drug c a te g o rie s  Re c re a tio na l vs OMMP c a nna b is use rs  Ca nna b is pro duc t type  Blo o d te sting fo r drug s

DRE Blo o d T e sting Gra nt

 Ne w for

F F Y 2015- 2016 $60,000

 169 b lo o d sa mple s te ste d fo r 141 inc ide nts.  T

ra c king a va rie ty o f a spe c ts.

 I

nc ide nt type s

 Drug pre va le nc e  T

HC le ve ls

 Blo o d sa mple c o lle c tio n de la ys  DRE

e va lua tio ns a nd c o nfirma tio n %

 Re ne we d for

F F Y 2016- 2017 $120,000

Q & A